Business Wire

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 ...
Nasdaq

QuidelOrtho Receives FDA Clearance For QuickVue COVID-19 Test - Quick Facts

(RTTNews) - QuidelOrtho (QDEL) said it has received FDA 510(k) clearance for QuickVue COVID-19 test. The clearance allows the test to be used in home and medical facility settings with CLIA ...
Hosted on MSN

QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test

Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...
Nasdaq

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

Designed for symptomatic individuals within six days of symptom onset, the QuickVue COVID-19 test is cleared for use in individuals aged 14 or older when self-testing, and in those aged two and older ...